{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,19]],"date-time":"2025-04-19T04:19:23Z","timestamp":1745036363517,"version":"3.37.3"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T00:00:00Z","timestamp":1701043200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T00:00:00Z","timestamp":1701043200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1007\/s12185-023-03678-9","type":"journal-article","created":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T10:04:08Z","timestamp":1701079448000},"page":"88-92","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Effectiveness of venetoclax and azacytidine against myeloid\/natural killer cell precursor acute leukemia"],"prefix":"10.1007","volume":"119","author":[{"given":"Ichiro","family":"Shiomi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soichiro","family":"Nakako","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5521-4247","authenticated-orcid":false,"given":"Takahiko","family":"Nakane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yumi","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taku","family":"Araki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yotaro","family":"Fujitani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryosuke","family":"Yamamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayuki","family":"Hino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirohisa","family":"Nakamae","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,11,27]]},"reference":[{"issue":"6","key":"3678_CR1","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1182\/blood.V90.6.2417","volume":"90","author":"R Suzuki","year":"1997","unstructured":"Suzuki R, Yamamoto K, Seto M, Kagami Y, Ogura M, Yatabe Y, et al. CD7+ and CD56+ myeloid\/natural killer cell precursor acute leukemia: a distinct hematolymphoid disease entity. Blood. 1997;90(6):2417\u201328.","journal-title":"Blood"},{"issue":"4","key":"3678_CR2","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1111\/j.1365-2141.2007.06835.x","volume":"139","author":"K Oshimi","year":"2007","unstructured":"Oshimi K. Progress in understanding and managing natural killer-cell malignancies. Br J Haematol. 2007;139(4):532\u201344.","journal-title":"Br J Haematol"},{"key":"3678_CR3","volume-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","author":"SH Swerdlow","year":"2017","unstructured":"Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2017."},{"issue":"5","key":"3678_CR4","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1007\/BF02986617","volume":"77","author":"R Suzuki","year":"2003","unstructured":"Suzuki R, Murata M, Kami M, Ohtake S, Asou N, Kodera Y, et al. Prognostic significance of CD7+CD56+ phenotype and chromosome 5 abnormalities for acute myeloid leukemia M0. Int J Hematol. 2003;77(5):482\u20139.","journal-title":"Int J Hematol"},{"issue":"7","key":"3678_CR5","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/S0145-2126(98)00194-5","volume":"23","author":"R Suzuki","year":"1999","unstructured":"Suzuki R, Nakamura S. Malignancies of natural killer (NK) cell precursor: myeloid\/NK cell precursor acute leukemia and blastic NK cell lymphoma\/leukemia. Leuk Res. 1999;23(7):615\u201324.","journal-title":"Leuk Res"},{"issue":"6","key":"3678_CR6","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1002\/ccr3.1506","volume":"6","author":"Y Noguchi","year":"2018","unstructured":"Noguchi Y, Tomizawa D, Hiroki H, Miyamoto S, Tezuka M, Miyawaki R, et al. Hematopoietic cell transplantation for myeloid\/NK cell precursor acute leukemia in second remission. Clin Case Rep. 2018;6(6):1023\u20138.","journal-title":"Clin Case Rep"},{"issue":"2","key":"3678_CR7","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/S1470-2045(08)70314-0","volume":"10","author":"E Coustan-Smith","year":"2009","unstructured":"Coustan-Smith E, Mullighan CG, Onciu M, Behm FG, Raimondi SC, Pei D, et al. Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol. 2009;10(2):147\u201356.","journal-title":"Lancet Oncol"},{"issue":"1","key":"3678_CR8","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1111\/bjh.15503","volume":"183","author":"S Fuhrmann","year":"2018","unstructured":"Fuhrmann S, Schabath R, M\u00f6ricke A, Zimmermann M, Kunz JB, Kulozik AE, et al. Expression of CD56 defines a distinct subgroup in childhood T-ALL with inferior outcome. Results of the ALL-BFM 2000 trial. Br J Haematol. 2018;183(1):96\u2013103.","journal-title":"Br J Haematol"},{"issue":"4","key":"3678_CR9","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.it.2006.02.004","volume":"27","author":"H Kawamoto","year":"2006","unstructured":"Kawamoto H. A close developmental relationship between the lymphoid and myeloid lineages. Trends Immunol. 2006;27(4):169\u201375.","journal-title":"Trends Immunol"},{"issue":"7188","key":"3678_CR10","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1038\/nature06839","volume":"452","author":"H Wada","year":"2008","unstructured":"Wada H, Masuda K, Satoh R, Kakugawa K, Ikawa T, Katsura Y, et al. Adult T-cell progenitors retain myeloid potential. Nature. 2008;452(7188):768\u201372.","journal-title":"Nature"},{"issue":"12","key":"3678_CR11","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1016\/j.leukres.2010.06.020","volume":"34","author":"M Morimoto","year":"2010","unstructured":"Morimoto M, Kondoh K, Keino D, Ohyama R, Ban S, Kinoshita A, et al. A child with myeloid\/natural killer cell precursor acute leukemia treated successfully with acute myeloid leukemia-oriented chemotherapy incorporating L-asparaginase. Leuk Res. 2010;34(12):1677\u20139.","journal-title":"Leuk Res"},{"issue":"7","key":"3678_CR12","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1002\/pbc.22758","volume":"55","author":"N Shiba","year":"2010","unstructured":"Shiba N, Kanazawa T, Park MJ, Okuno H, Tamura K, Tsukada S, et al. NOTCH1 mutation in a female with myeloid\/NK cell precursor acute leukemia. Pediatr Blood Cancer. 2010;55(7):1406\u20139.","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"3678_CR13","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/BF02982029","volume":"75","author":"K Tezuka","year":"2002","unstructured":"Tezuka K, Nakayama H, Honda K, Suzumiya J, Oshima K, Kitoh T, et al. Treatment of a child with myeloid\/NK cell precursor acute leukemia with L-asparaginase and unrelated cord blood transplantation. Int J Hematol. 2002;75(2):201\u20136.","journal-title":"Int J Hematol"},{"issue":"5","key":"3678_CR14","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1182\/bloodadvances.2020003734","volume":"5","author":"M Stahl","year":"2021","unstructured":"Stahl M, Menghrajani K, Derkach A, Chan A, Xiao W, Glass J, et al. Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed\/refractory AML. Blood Adv. 2021;5(5):1552\u201364.","journal-title":"Blood Adv"},{"issue":"Supplement 1","key":"3678_CR15","doi-asserted-by":"publisher","first-page":"4418","DOI":"10.1182\/blood-2021-151287","volume":"138","author":"JM Unglaub","year":"2021","unstructured":"Unglaub JM, Schlenk RF, Hanoun M, Reinhardt HC, Middeke JM, Sch\u00e4fer-Eckart K, et al. Venetoclax-azacitidine as salvage therapy and bridge to allogeneic cell transplantation in relapsed\/refractory AML compared to historical data of the SAL registry study. Blood. 2021;138(Supplement 1):4418.","journal-title":"Blood"},{"issue":"3","key":"3678_CR16","doi-asserted-by":"publisher","first-page":"708","DOI":"10.3324\/haematol.2018.214882","volume":"105","author":"H Kuusanm\u00e4ki","year":"2020","unstructured":"Kuusanm\u00e4ki H, Lepp\u00e4 AM, P\u00f6l\u00f6nen P, Kontro M, Dufva O, Deb D, et al. Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia. Haematologica. 2020;105(3):708\u201320.","journal-title":"Haematologica"},{"issue":"13","key":"3678_CR17","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1182\/blood.2020006785","volume":"138","author":"AW Roberts","year":"2021","unstructured":"Roberts AW, Wei AH, Huang DCS. BCL2 and MCL1 inhibitors for hematologic malignancies. Blood. 2021;138(13):1120\u201336.","journal-title":"Blood"},{"issue":"4","key":"3678_CR18","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1158\/2159-8290.CD-19-0710","volume":"10","author":"S Pei","year":"2020","unstructured":"Pei S, Pollyea DA, Gustafson A, Stevens BM, Minhajuddin M, Fu R, et al. Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Patients with Acute Myeloid Leukemia. Cancer Discov. 2020;10(4):536\u201351.","journal-title":"Cancer Discov"},{"issue":"9","key":"3678_CR19","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1158\/2159-8290.CD-14-0353","volume":"4","author":"TN Chonghaile","year":"2014","unstructured":"Chonghaile TN, Roderick JE, Glenfield C, Ryan J, Sallan SE, Silverman LB, et al. Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199. Cancer Discov. 2014;4(9):1074\u201387.","journal-title":"Cancer Discov"},{"issue":"25","key":"3678_CR20","doi-asserted-by":"publisher","first-page":"3738","DOI":"10.1182\/blood-2014-05-574566","volume":"124","author":"S Peirs","year":"2014","unstructured":"Peirs S, Matthijssens F, Goossens S, Van de Walle I, Ruggero K, de Bock CE, et al. ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia. Blood. 2014;124(25):3738\u201347.","journal-title":"Blood"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-023-03678-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-023-03678-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-023-03678-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T12:25:30Z","timestamp":1704457530000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-023-03678-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,27]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["3678"],"URL":"https:\/\/doi.org\/10.1007\/s12185-023-03678-9","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"type":"print","value":"0925-5710"},{"type":"electronic","value":"1865-3774"}],"subject":[],"published":{"date-parts":[[2023,11,27]]},"assertion":[{"value":"12 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest in association with the present study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}